Johnson & Johnson Vaccine Paused; Here Is Why!
Several states pause Johnson & Johnson vaccine after CDC and FDA recommendation over six rare blood clotting cases. Continue on…
CelebnHealth247.com has the latest on the one shot Johnson & Johnson vaccine for COVID-19.
The US Centers for Disease Control and Food and Drug Administration released a joint statement on Tuesday recommending a pause in administering the Johnson & Johnson COVID-19 vaccine out of “an abundance of caution” while an investigation is conducted into reports of rare blood clotting.
Here is what has been reported thus far:
Six cases were detected in more than 6.8 million doses of the vaccine. Johnson & Johnson is also delaying its vaccine rollout in Europe. According to Dr. Anne Schuchat of the CDC, people who received the J&J vaccine more than a month ago are at minimal risk. Biden administration officials say that the pause “will not have a significant impact on our vaccination plan.”
Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine:
The statement reads as follows:
As of April 12, more than 6.8 million doses of the Johnson & Johnson (Janssen) vaccine have been administered in the U.S. CDC and FDA are reviewing data involving six reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the J&J vaccine. In these cases, a type of blood clot called cerebral venous sinus thrombosis (CVST) was seen in combination with low levels of blood platelets (thrombocytopenia). All six cases occurred among women between the ages of 18 and 48, and symptoms occurred 6 to 13 days after vaccination. Treatment of this specific type of blood clot is different from the treatment that might typically be administered. Usually, an anticoagulant drug called heparin is used to treat blood clots. In this setting, administration of heparin may be dangerous, and alternative treatments need to be given.
CDC will convene a meeting of the Advisory Committee on Immunization Practices (ACIP) on Wednesday to further review these cases and assess their potential significance. FDA will review that analysis as it also investigates these cases. Until that process is complete, we are recommending a pause in the use of this vaccine out of an abundance of caution. This is important, in part, to ensure that the health care provider community is aware of the potential for these adverse events and can plan for proper recognition and management due to the unique treatment required with this type of blood clot.